Preventing Osteoporosis and Reducing Fracture Risk - PowerPoint PPT Presentation

1 / 68
About This Presentation
Title:

Preventing Osteoporosis and Reducing Fracture Risk

Description:

Preventing Osteoporosis and Reducing Fracture Risk Usman Malabu; FACP, FRCPI, FRACP Staff Endocrine Specialist & Assoc. Prof. of Medicine The Townsville Hospital ... – PowerPoint PPT presentation

Number of Views:376
Avg rating:3.0/5.0
Slides: 69
Provided by: UsmanM
Category:

less

Transcript and Presenter's Notes

Title: Preventing Osteoporosis and Reducing Fracture Risk


1
Preventing Osteoporosis and Reducing Fracture Risk
Usman Malabu FACP, FRCPI, FRACP Staff Endocrine
Specialist Assoc. Prof. of Medicine The
Townsville Hospital James Cook
University Townsville, North Queensland -Australia
2
Case Presentation
  • 68 year old female Mrs. KY
  • CXR for cough osteopenic bones

3
Outline Management Plan
  • What further history
  • Clinical examination
  • Investigations
  • Treatment Prevention

4
History Mrs. KY
  • Hx of Prior Fractures
  • Falls Hx
  • Neurological D-Z Hx
  • Hx of Muscular Weakness
  • Nutritional Hx
  • Medication Hx
  • Functional Hx

5
Nutritional History Mrs. KY
  • Deficiency States
  • Calcium
  • Vitamin D
  • Vitamin C
  • Excess Intake
  • Caffeine
  • Alcohol
  • Smoking

6
Physical Examination Mrs. KY
  • Orthostatics
  • Gait Mobility
  • Height
  • Kyphosis
  • Clinical Features of
  • Hypercortisolism
  • Hyperthyroid

7
Evaluation for Suspected Osteoporosis in Selected
Patients
Test Possible etiology
Alkaline phosphates Osteomalacia
Calcium Vitamin D deficiency Malabsorption Hyperparathyroidism
Liver or kidney function Liver or kidney disease
TSH Hyperthyroidism
Total testosterone (men) Hypogonadism
25-hydroxyvitamin D Vitamin D deficiency
Complete blood count Multiple myeloma Malabsorption
8
Evaluation for Osteoporosis in Selected Patients
Test Possible etiology
FSH, LH, Estradiol (women) Hypogonadism
PTH Hyperparathyroidism
ESR, uBJP Multiple myeloma
CTX bone turn over marker Assess activity of osteoporosis
9
Hip
BMD
Spine
10
WHO Definitions
11
Bone Health
Normal
Osteoporotic
Bone quality is not the only factor
12
Diagnosis of Osteoporosis
  • History etiology and RFs
  • Exam kyphosis, prox weakness
  • X-rays fractures
  • BMD bone mass
  • Laboratory tests etiology, BTOM

13
  • After mid-30s slow loss
  • Post-menopause rapid loss
  • Men lose bone mass too.

Source The 2004 Surgeon Generals Report on Bone
Health and Osteoporosis What It Means to You at
http//www.surgeongeneral.gov/library/bonehealth
14
The Domino Fracture Effect
14
15
Fracture Risk Reduction
  • Minimize over-zealous Rx of those at
    indeterminate risk
  • Look for risk factors other than low bone mineral
    density

16
Fracture Risk Assessment
  • Developed by WHO FRAX
  • Enhances ability to predict fracture risk
  • BMI of femoral neck
  • Clinical risk factors
  • ABSOLUTE RISK 10-year period
  • gt3 for hip fracture
  • gt15 for major fractures

FRAX. Available at http//www.shef.ac.uk/FRAX/in
dex.htm.
17
Prof. John A KanisUniversity of Sheffield
FRAX. Available at http//www.shef.ac.uk/FRAX/in
dex.htm.
18
(No Transcript)
19
(No Transcript)
20
Risk factors
The red flags for osteoporosis risk.
21
IDENTIFY RISK FACTORS OF OSTEOPOROSIS
1
  • Older than 65
  • after age 50
  • Underweight
  • Previous falls
  • FMH of Osteo/

22
IDENTIFY RISK FACTORS OF OSTEOPOROSIS
2
  • Smoking
  • gt 2 drinks of alcohol/week

23
  • RISK FACTORS CURRENT OR PMH
  • Cancer
  • Chronic lung disease
  • Chronic liver or kidney disease
  • Inflammatory bowel disease
  • Rheumatoid arthritis
  • Hyperparathyroidism
  • Vitamin D deficiency
  • Cushing's syndrome
  • Hyperthyroidism

3
24
RISK FACTORS OF OSTEOPOROSIS MEDICATIONS
4
  • One of these medicines
  • Oral glucocorticoids (steroids)
  • TZDs pioglitazone
  • PPIs
  • Cancer treatments (radiation, chemo)
  • Thyroxine
  • Antiepileptic medications phenytoin, CMZ
  • Gonadal hormone suppression -medroxyprog
  • Immunosuppressive agents

25
The good news Osteoporosis is preventable for
most people!
  • Diet and lifestyle

26
(No Transcript)
27
Management of Osteoporosis
  • Prevention / Primary Prevention
  • Lifestyle
  • Diet
  • Exercise
  • Smoking
  • Alcohol Intake
  • Sunlight Exposure
  • Pharmacological
  • Drugs altering BMD
  • Non-pharmacological
  • Physiotherapy
  • Hip Protectors
  • Treatment / Secondary Prevention
  • Lifestyle
  • Diet
  • Exercise
  • Smoking
  • Alcohol Intake
  • Sunlight Exposure
  • Pharmacological
  • Drugs altering BMD
  • Analgesia
  • Non-pharmacological
  • Physiotherapy
  • Pain Relief
  • Falls Assessment

Prevention of Falls
28
Lifestyle Advice
Diet Balanced diet containing adequate
calcium 1000 mg/day
Exercise Regular weight bearing exercise 3 times
a week for 20 minutes minimum
Smoking Stop smoking
Sunlight Exposure 15-20 minutes on face, hands
and forearms twice weekly form April to October
  • Alcohol
  • Within safe limits
  • 2u/day women
  • 3u/day men

29
Calcium Rich Diet Vitamin D Prevent
Falls Weight-Bearing Exercise
30
(No Transcript)
31
Walking Dancing Gardening Tennis Jump
Rope Volleyball Skating
Activity Exercise Guide
32
Dont Smoke Minimize Caffeine Alcohol Testing
Medication if Needed
33
Calcium Requirements age related
Goal
500 mg 1,300 mg
http//www.osteoporosis.org.au/news/latest-news/ne
w-guidelines-released-in-mja-open/
34
Dietary sources of calcium
  • Dairy foods
  • Most readily absorbed Ca
  • Main source of calcium in Australian diets
  • RDI ?3 serves per day
  • Ca-enriched soy drinks
  • Fish with bones

RDI for older people 1300 mg
4.5 glasses of milk
http//www.racgp.org.au/download/documents/Guideli
nes/Musculoskeletal/racgp_osteo_guideline.pdf
35
(No Transcript)
36
  • Vitamin D for Ca absorption
  • 400 IU daily
  • Vitamin D is in milk (100 IU in 1 cup)

37
(No Transcript)
38
Current treatments in OP
  • Antiresorptive
  • Estrogens and SERMs
  • Calcitonin
  • Bisphosphonates
  • Denosumab
  • Anabolic (stimulate bone formation)
  • Parathyroid hormone
  • Dual action agents
  • Strontium ranelate

39
Estrogen
  • ERT increases BMD gt SERM
  • Prestwood, KM et al. J Clin Enodocrinol Metab.
    2000 85(6) 2197-2202
  • WHI raised concerns about CV risks
  • E2 still approved for hot flashes
  • Low-dose ERT at menopause will delay bone
    thinning not as first-line therapy

40
HRT A CONSENSUS
  • Prime role of HRT is relief of menopausal Sx
  • Risks/benefits breast Ca 2-6/1000 women treated
    with HRT for 5 years
  • Use lowest effective E2 dose, assess CV risk
  • Review need annually (esp agedgt60)

41
HRT A CONSENSUS
  • Can give up to age 50 if prem menopause
  • Do not use in IHD/CVA, or Alzheimer's
  • Transdermal E2 has lower DVT risk

42
RALOXIFENE -SERMS
  • Reduces vertebral (not hip) fracture risk
  • Reduces development of new breast Ca
  • No increased risk of CVD (reduces CV events!)
  • Increased risk of DVT/PE may worsen flushes
  • Well tolerated, easy dosing 60 mg OD

43
Calcitonin
  • Calcitonin is effective for OP fracture pain
  • Effect takes about 2 weeks.
  • Silverman, SL. Osteoporos Int. Nov
    200213(11)858-867.
  • No significant effect in the hip

44
Bisphosphonates
  • Binds to bone
  • Inhibits osteoclast activity
  • Supports osteoblast bone formation
  • First line treatment for osteoporosis

45
Bisphosphonates
  • Alendronate (Fosamax) generic
  • Risedronate (Actonel) better GI profile
  • Ibandronate (Boniva) no hip protection
  • Zoledronic Acid (Aclasta) once a year

46
Unusual Complications of BisPO4s
  • Osteonecrosis of jaw-
  • Rare 1/100,000 patient years
  • 94 in cancer patients receiving zoledronic acid
    or pamidronate

Woo S-B, et al. 2006 Ann Int Med 144(10)753-61
47
5/10,000 risk gt 5 yrs Rx
Atypical
NEJM 36418 nejm.1730 org may 5, 2011
48
Strontium ranelate
  • In women with postmenopausal osteoporosis
  • Recent indication Severe osteoporosis
  • 3rd line used to be alternative to bisPO4s
    elderly
  • if potential for GI complications
  • Beware rash (DRESS), VTE MI
  • Contraindication IHD, PVD, CVA

MHRA Drug Safety Update 2013 6(9).
49
Denosumab (Prolia)
  • Monoclonal Ab to RANKL which drives osteoclasts
  • Subcut every 6/12! 60mg
  • Dramatic and quick effect
  • Fracture reduction similar to Zoledronate
  • Used in renal failure

50
Parathyroid Hormone (PTH)
  • Forteo (Teriparatide)
  • 3rd line, use for 18 months
  • Daily 20mg or 0.08ml SQ injection
  • Intermittent antiresorptive effect
  • Preferential osteoblastgtosteoclast activity

51
PROLIA REAL WORLD
Factors influencing treatment
Efficacy
Adherence
Cost
Convenience/patient choice
Safety/tolerability
52
Osteoporosis Prevention and Treatment
Hormonal Replacement
SERM
Treatment choice
PTH
Vitamin D
Life Style
20
40
60
80
Age
53
Summary of Medications
  • Bisphosphonates- First line therapy
  • Must have GFR gt 30
  • Denosumab, 2x/yr useful in low eGFR
  • Strontium 3rd line C/I IHD
  • PTH 3rd line use lt2yrs
  • Estrogen for post-menopause symptoms
  • SERM spine only

54
OP When to refer to Specialist?
  • Rx side effects
  • Other complex medical conditions
  • Inadequate response to Rx
  • Vertebral fracture
  • lt50 years
  • Identified secondary cause
  • Continue to with normal BMD

http//ebooks.adelaide.edu.au/dspace/bitstream/244
0/39778/1/hdl_39778.pdf
55
Calcium/Vitamin D Controversies
  • Ca/Vit D tablets harm/benefit

56
Background
  • 36, 282 postmenopausal WHI
  • 1 G Ca 400 IU VitD or Placebo for 7 years
  • Baseline 20,000 on personal Ca
  • Baseline 16,000 no Ca

Bolland MJ et al. BMJ 2011 9342d2040
57
RESULTS
ANY Personal Calcium Use
NO Personal Calcium Use
Event CaD N8429 Placebo N8289 HR 95 CI P CaD N8429 Placebo N8289 HR 95 CI P
MI 209 168 1.2 (1-1.5) 0.05 180 196 0.92 (0.75-1.1) 0.44
CVA 196 163 1.2 (0.9-1.4) 0.14 156 189 0.8 (0.7-1) 0.08
MI/ CVA 386 326 1.16 (1-1.4) 0.05 324 370 0.9 (0.76-1) 0.09
Bolland MJ et al. BMJ 2011 9342d2040
58
Bolland MJ et al. BMJ 2011 9342d2040.
59
Bolland MJ et al. BMJ 2011 9342d2040.
60
Incidence of MI/CVA in Subjects on Calcium
Bolland MJ et al. BMJ 2011 9342d2040.
61
Ca-VitD Incidence of Death
Bolland MJ et al. BMJ. 2010341c3691.
62
Making Sense of the Results
  • 1000 treated with Ca Vit D for 5 years
  • MIs 4X
  • Stroke 4X
  • Death 2X
  • 3 fractures would be prevented

63
Calcium Risk of Death Men vs Women
Xiao Q et al. JAMA Intern Med. 2013173(8)639-46.

64
Calcium Risk of Death Men vs Women
Xiao Q et al. JAMA Intern Med. 2013173(8)639-46
65
Implication for Clinical Practice
  • Recommendation for widespread use of Ca Rx no
    longer appropriate
  • Calcium/vitamin D-rich diet favoured
  • Further studies needed

66
Bone Health Building Blocks
67
Conclusion
  • Osteoporosis is a growing epidemic
  • Preach prevention!
  • DEXA for all women gt65, and others
  • Treat all elderly, and patients at risk, with
    diet-rich Calcium and Vitamin D
  • Dont be afraid of bisphosphonates

68
Thank You
Write a Comment
User Comments (0)
About PowerShow.com